Canadian health data company Avricore Health said on Tuesday that it has signed a letter of intent to work with Avrok Laboratories to offer rapid SARS-CoV-2 antigen testing for international travelers.
Avrok, which operates a CLIA-certified lab in California, will oversee the testing of travelers in Canada, the US, Mexico, and the Caribbean, for example at resorts and through airlines. The test results will then be reported directly via Avricore’s HealthTab point-of-care screening and test result management platform.
Avricore said that the letter of intent includes a revenue sharing agreement between the companies based on contracts secured with resorts, airlines, and other organizations engaged in SARS-CoV-2 travel testing. Additional terms were not disclosed.
“HealthTab is getting a great deal of interest from the travel and airline industry who need fast, secure communication of test results,” Avricore CEO Hector Bremner said in a statement. “An agreement with Avrok Laboratories means we now have a strong partner validating test results being reported through us and we can now offer the type of service resorts and airlines are asking for.”